Company: FENC
Filing Date: 2025-12-02
Form Type: 8-K
Source: 0001104659-25-117697
Chunk: 0

Company: FENNEC PHARMACEUTICALS INC.
Filing Date: 2025-12-02
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01.      Other Events.  

On December 2, 2025, Fennec Pharmaceuticals Inc. issued a news release and announced positive topline results
from the investigator-initiated Phase 2/3 STS-J01 clinical trial evaluating PEDMARK ® ®

The information contained in this Current Report on Form 8-K, including the exhibit attached hereto, is being
furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “ Exchange
Act”), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent
filing specifically references this Form 8-K.